2-hexylcyclopent-2-enone

Endpoint summary

Description of key information

Oral LD50 is >5000 mg/kg bw

Dermal LD50 is >5000 mg/kg bw

Key value for chemical safety assessment

Acute toxicity: via oral route

Link to relevant study records

Reference

Endpoint:

acute toxicity: oral

Type of information:

experimental study

Adequacy of study:

key study

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

comparable to guideline study with acceptable restrictions

Qualifier:

equivalent or similar to guideline

Guideline:

OECD Guideline 401 (Acute Oral Toxicity)

GLP compliance:

no

Test type:

standard acute method

Limit test:

yes

Species:

rat

Strain:

not specified

Sex:

not specified

Route of administration:

oral: unspecified

Vehicle:

not specified

Doses:

5000 mg/kg bw

No. of animals per sex per dose:

10 animals used

Control animals:

no

Details on study design:

- Duration of observation period following administration: 14 days
- Examinations performed: mortality and toxicity

Key result

Sex:

not specified

Dose descriptor:

discriminating dose

Effect level:

5 000 mg/kg bw

Based on:

test mat.

Mortality:

No mortality observed

Clinical signs:

other: Diarrhea was observed on day 1 and 2. Lethargy was observed on day 4.

Interpretation of results:

GHS criteria not met

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Dose descriptor:

discriminating dose

Value:

5 000 mg/kg bw

Quality of whole database:

One Klimisch 2 study available. Performed similar to guideline.

Acute toxicity: via inhalation route

Endpoint conclusion

Endpoint conclusion:

no study available

Acute toxicity: via dermal route

Link to relevant study records

Reference

Endpoint:

acute toxicity: dermal

Type of information:

experimental study

Adequacy of study:

key study

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

comparable to guideline study with acceptable restrictions

Qualifier:

equivalent or similar to guideline

Guideline:

OECD Guideline 402 (Acute Dermal Toxicity)

GLP compliance:

no

Test type:

standard acute method

Limit test:

yes

Species:

rabbit

Strain:

not specified

Sex:

not specified

Type of coverage:

not specified

Vehicle:

not specified

Doses:

5000 mg/kg bw

Control animals:

no

Details on study design:

- Duration of observation period following administration: 14 days
- Examinations performed: mortality, toxicity and skin irritation

Key result

Sex:

not specified

Dose descriptor:

discriminating dose

Effect level:

5 000 mg/kg bw

Based on:

test mat.

Mortality:

One animal died on day 3

Clinical signs:

other: No toxicity observed

Other findings:

Skin irritation: Slight redness 2/10; Moderate redness 8/10; Slight edema 4/10; Moderate edema 6/10

Interpretation of results:

GHS criteria not met

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Dose descriptor:

discriminating dose

Value:

5 000 mg/kg bw

Quality of whole database:

One Klimisch 2 study available. Performed similar to guideline.

Additional information

Acute oral toxicity:

In an acute oral toxicity study performed similar to OECD 401, the test substance was administered via the oral route to ten rats. The concentration administered was 5000 mg/kg bw and the animals were observed for 14 days. No mortality was observed. Diarrhea was observed on day 1 and 2 and lethargy was observed on day 4. The LD50 was determined to be >5000 mg/kg bw.

Acute dermal toxicity:

In an acute dermal toxicity study performed similar to OECD 402, the test substance was administered dermally to ten rabbits. The concentration applied was 5000 mg/kg bw and the animals were observed for 14 days. One animal died on day 3. No toxic effects were observed. The LD50 was determined to be >5000 mg/kg bw.

Justification for classification or non-classification

The test substance does not have to be classified for acute oral or dermal toxicity according to Regulation (EC) No 1272/2008.